Cannabis Science Inc (fka CBIS)

[mick]

thank you, interesting ????? Cannabis Science, Inc: Analyst Initiates Coverage w/ ‘Accumulate’ Recommendation and $0.10 PPS Target

http://ih.advfn.com/p.php?pid=nmona&article=69437715

Date : 11/23/2015 @ 2:00PM
Source : InvestorsHub NewsWire
Stock : Cannabis Science, Inc. (PC) (CBIS)
Quote : 0.0191 -0.0009 (-4.50%) @ 5:00PM
Cannabis Science, Inc: Analyst Initiates Coverage w/ ‘Accumulate’ Recommendation and $0.10 PPS Target
Print
Alert
New York, NY -- November 23, 2015 -- InvestorsHub NewsWire -- Wall Street Corner today released an analyst report from Caprock Research on Cannabis Science, Inc. (OTC PINK:CBIS), a U.S. company specializing in the development of cannabis-based medicines. The analyst authoring the report initiated coverage with an 'Accumulate' recommendation and a near term target price per share of $0.05 with a long term target price per share of $0.10.

The full report is available on the Wall Street Corner Special Situation Report website:

WALL STREET CORNER SPECIAL SITUATION REPORT - CBIS

Caprock Research has been engaged by Wall Street Corner to conduct ongoing analyst research in conjunction with Wall Street Corner’s Special Situation Report. Wall Street Corner periodically features small and micro cap companies in an ethical and professional manner that it believes to be undervalued.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact:
Wall Street Corner
Larry Oakley
[e-mail]
843.645.2729